대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	Comparative analysis of the impact of febuxostat and allopurinol on glomerular filtration rate and hyperuricemia in chronic kidney disease patients
저자	Mohan V Bhojaraja
출판정보	2024; 2024(1):
키워드
초록	Objectives: To compare the efficacy of febuxostat against allopurinol on the progression of CKD and hyperuricemia Methods: A retrospective case-record study was performed at our tertiary care hospital between January 2019 and December 2022 visiting the renal clinic following institutional ethical approval.In this study, we assessed the impact of febuxostat versus allopurinol on the progression of CKD and hyperuricemia in stage 3–4 CKD patients treated with either medication for a minimum of 6 months due to hyperuricemia (>7 mg/dL). Baseline characteristics, serum uric acid (SUA), serum creatinine, and estimated glomerular filtration rate (eGFR) at entry and six months were compared. The primary outcome focused on the decline in eGFR, with secondary outcomes including reductions in SUA and adverse events. Results: Among 101 patients, febuxostat was given to 54 patients, while 47 were in the allopurinol group.The mean doses of febuxostat and allopurinol were 43.70 ± 14.5 mg and 108.51 ± 40 mg, respectively. After 6 months, the median rate of eGFR decline was 1.2 mL/min/1.73 m² (IQR 1.2, 5.5) for the febuxostat group and 3.1 mL/min/1.73 m² (0.6, 6.2) for the allopurinol group. Still, this difference did not reach statistical significance (P = 0.136). The febuxostat group exhibited a significantly greater mean reduction in SUA (3.9 ± 1.7 mg/dL) compared to the allopurinol group (2.1 ± 1.0 mg/dL) (P = 0.004). Notably, both medications were well-tolerated with no reported serious adverse events. Conclusions: Febuxostat reduced hyperuricemia more effectively than allopurinol in patients with stage 3 and 4 CKD, but there was no significant difference in the progression of CKD.Large randomized trials and long-term follow-up are necessary to determine whether febuxostat has a beneficial effect on the progression of CKD.
원문(PDF)	PDF 원문보기

목록

위로가기